预测市场赔率:FDA approves skin cancer vaccine by...?

常见问题

没有找到你需要的答案?请联系我们,我们会尽快回复。

这是一个{category}预测市场,您可以押注自己预期的“{event}”结果。赔率会随新闻动态和市场需求实时波动,待结果依据规则确认后,市场即进行结算。

{leader} 目前是最有可能的结果,概率为 {chance}。该数据会实时更新,下注前请查看盘口了解最新赔率。

该盘口预计于{endDate}结束。具体的结算方式和结算时间均在盘口规则中有详细说明,建议您在下注前先到盘口页面仔细阅读。

先注册账户,使用加密货币充值,然后进入对应盘口并选择您看好的结果。在投注单中确认投注金额,并关注赔率变化,直至盘口结算。如果您是新手,可以参阅我们的新手玩家完整使用指南,逐步了解每个环节。

不是。{chance} 只是大众目前的预估,并不是一定会成真的预测,任何结果都有可能落空。请将预测市场视为一种娱乐方式,在参与前先设定好限额;如果您希望保持健康的游戏习惯,请阅读我们的理性控制小贴士。

目前 Yes 以 67% 成为“FDA approves skin cancer vaccine by...?”最有可能的结果。选择你看好的一方,并实时关注赔率,直至市场预计于 2028年1月1日 结束。

预测市场赔率:FDA approves skin cancer vaccine by...?

押注结果:FDA approves skin cancer vaccine by...?

“FDA approves skin cancer vaccine by...?”市场现已在 BiggerZ 开放,目前 Yes 以 67% 成为最有可能的结果。赔率反映了大众此刻的预期,并会随新闻发布而变动,局势可能瞬息万变。该市场预计于 2028年1月1日 结束。选择你看好的结果,关注实时赔率,并通过 BiggerZ 加密货币优先投注平台管理一切,同一账户还可畅玩在线赌场。

想要对比?前往 BiggerZ 浏览更多预测市场。

什么是“FDA approves skin cancer vaccine by...?”市场?

这是一个Politics预测市场:围绕现实事件的某个问题而设的实时市场。你可以押注自己认为最可能发生的结果,赔率则显示大众此刻对各个选项的看法。每个市场都有各自的结算规则,说明何种情况算作结果以及市场何时结算。

如何解读赔率

目前,Yes 以 67% 领先。请把这个数字看作大众对该结果可能性的当前估计,而不是保证。百分比越高,说明大众认为该结果越可能发生;越低则越不可能。每当新信息改变预期,数字就会变化,因此今天的热门下周未必还是热门。

如何参与“FDA approves skin cancer vaccine by...?”市场交易

  1. 查看赔率。了解谁或什么领先,以及其他结果的对比情况。
  2. 选择结果。押注你预期的那一个。
  3. 关注市场。随着事态发展,实时观察赔率变动。
  4. 等待结果。结果按规则确认后,市场即进行结算。

初次接触这种玩法?了解预测市场如何在 BiggerZ 上线,或按照我们的新手入门指南,从注册一直到完成首次投注。

哪些因素会影响赔率

  • 新闻与公告。官方声明、赛果和突发消息可能在几分钟内改变预期。
  • 数据与既定事件。数据发布、投票、截止日期和会议往往是转折点。
  • 公众情绪。随着越来越多的人选边站,赔率会随之调整以反映大众观点。
  • 结束日期。该市场预计于 2028年1月1日 结束,越临近该日期,赔率往往越明朗。请务必查看市场规则,了解具体的结算方式和时间。

为什么在 BiggerZ 关注这个市场?

一个账户,畅享所有产品

预测市场、体育博彩和赌场共用一个钱包。在关注“FDA approves skin cancer vaccine by...?”的间隙,你可以直接畅玩加密货币赌场游戏,无需重新开始。

为加密货币而生

可使用主流币种和稳定币为账户充值,非常适合与数字资产相关的市场。

通用的奖励

查看我们的优惠活动了解当前有哪些优惠,并加入 BiggerZ VIP 计划,随着活跃度提升享受分级特权。请务必阅读各项优惠的条款,确认是否适用于预测市场。

想换换口味时

赔率变动之时,平台的其他精彩内容也触手可及。你可以旋转加密货币老虎机,在真人荷官赌场入座,或试玩我们的原创赌场游戏。在热门赌场游戏中看看玩家们现在都在玩什么,发现最新赌场游戏,通过实时 RTP 追踪器比较回报率,或参加我们的赌场锦标赛争夺奖池。

理性预测

“FDA approves skin cancer vaccine by...?”市场属于娱乐,并非稳定的收入来源,再多的研究也无法消除亏损的风险。开始前请先设定预算,并且只投入你能承受损失的金额。我们的负责任博彩提示会介绍如何设置限额以及识别警示信号。您必须年满 18 周岁,服务是否可用取决于您所在的国家或地区。

关于FDA approves skin cancer vaccine by...?

截止于 2028年1月1日 · Politics, Tech

结果与赔率

结果概率赔率
Yes67%1.30
No33%2.64

结算规则

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program. Differences in neoantigen composition between patients will not affect resolution. Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above. Approval as part of a combination regimen will qualify. Approval for a narrower population than the one studied in INTerpath-001 will qualify. Approval for an indication other than melanoma will also qualify. Both standard and accelerated approval will qualify. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Act (PDUFA) dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source for this market will be official information from the FDA; however, a consensus of credible reporting may also be used.